Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 496775-61-2
Drug Levels and Effects
Summary of Use during Lactation
Minimal information is available on the use of eltrombopag during breastfeeding. One breastfed infant with thrombocytosis at birth that was possibly prolonged by eltrombopag in milk. Until more data become available, romiplostim should be used with careful infant monitoring of infant blood parameters during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends avoiding breastfeeding during the use of eltrombopag. Based on the drug’s half-life, the drug should be eliminated by the mother 8 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
An infant was born to a mother taking eltrombopag in a maximum dose of 100 mg during pregnancy. At birth, the infant had thrombocytosis, which persisted for a few weeks while the mother was breastfeeding. The extent of breastfeeding and the maternal dose were not stated. The authors felt that the persistence of thrombocytosis in the infant was possibly caused by eltrombopag in milk.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: Results from a multicenter study. Blood. 2020;136:3056–61. [PubMed: 32814348]
Substance Identification
Substance Name
Eltrombopag
CAS Registry Number
496775-61-2
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Romiplostim.[Drugs and Lactation Database (...]Review Romiplostim.. Drugs and Lactation Database (LactMed®). 2006
- Review Nivolumab.[Drugs and Lactation Database (...]Review Nivolumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Obinutuzumab.[Drugs and Lactation Database (...]Review Obinutuzumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Nilotinib.[Drugs and Lactation Database (...]Review Nilotinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Pertuzumab.[Drugs and Lactation Database (...]Review Pertuzumab.. Drugs and Lactation Database (LactMed®). 2006
- Eltrombopag - Drugs and Lactation Database (LactMed®)Eltrombopag - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...